Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sonya Sunhi Shin, M.D.

Co-Author

This page shows the publications co-authored by Sonya Shin and Jaime Bayona.
Connection Strength

3.020
  1. Mental Health Burden Among Impoverished HIV-Positive Patients in Peru. J Int Assoc Physicians AIDS Care (Chic). 2011 Jan-Feb; 10(1):18-25.
    View in: PubMed
    Score: 0.470
  2. How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community. 2011 May; 19(3):261-71.
    View in: PubMed
    Score: 0.468
  3. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study. BMC Infect Dis. 2016 Feb 01; 16:45.
    View in: PubMed
    Score: 0.167
  4. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2012 Nov; 16(11):1538-43.
    View in: PubMed
    Score: 0.132
  5. Community-based rapid oral human immunodeficiency virus testing for tuberculosis patients in Lima, Peru. Am J Trop Med Hyg. 2012 Sep; 87(3):399-406.
    View in: PubMed
    Score: 0.131
  6. Matching social support to individual needs: a community-based intervention to improve HIV treatment adherence in a resource-poor setting. AIDS Behav. 2011 Oct; 15(7):1454-64.
    View in: PubMed
    Score: 0.124
  7. Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIV-infected adults in urban Peru. AIDS Behav. 2011 Oct; 15(7):1483-9.
    View in: PubMed
    Score: 0.124
  8. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerg Infect Dis. 2011 Mar; 17(3):432-40.
    View in: PubMed
    Score: 0.119
  9. Microfinance: a general overview and implications for impoverished individuals living with HIV/AIDS. J Health Care Poor Underserved. 2010 Aug; 21(3):986-1005.
    View in: PubMed
    Score: 0.114
  10. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis. 2009 May 15; 48(10):1413-9.
    View in: PubMed
    Score: 0.105
  11. Community-based DOT-HAART accompaniment in an urban resource-poor setting. AIDS Behav. 2010 Jun; 14(3):721-30.
    View in: PubMed
    Score: 0.104
  12. Validation and abbreviation of an HIV stigma scale in an adult spanish-speaking population in urban Peru. AIDS Behav. 2010 Feb; 14(1):189-99.
    View in: PubMed
    Score: 0.101
  13. Scaling up HIV treatment in Peru: applying lessons from DOTS-Plus. J Int Assoc Physicians AIDS Care (Chic). 2006 Dec; 5(4):137-42.
    View in: PubMed
    Score: 0.088
  14. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006 Apr; 12(4):687-8.
    View in: PubMed
    Score: 0.084
  15. rpoB gene mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis in northern Lima, Peru. Microb Drug Resist. 2005; 11(1):26-30.
    View in: PubMed
    Score: 0.077
  16. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med. 2004 Oct; 59(7):1529-39.
    View in: PubMed
    Score: 0.076
  17. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis. 2003 Apr 15; 36(8):996-1003.
    View in: PubMed
    Score: 0.069
  18. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003 Apr; 7(4):347-53.
    View in: PubMed
    Score: 0.069
  19. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5.
    View in: PubMed
    Score: 0.053
  20. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76.
    View in: PubMed
    Score: 0.051
  21. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 10; 48(4):1160-1170.
    View in: PubMed
    Score: 0.043
  22. Reducing communication delays and improving quality of care with a tuberculosis laboratory information system in resource poor environments: a cluster randomized controlled trial. PLoS One. 2014; 9(4):e90110.
    View in: PubMed
    Score: 0.037
  23. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
    View in: PubMed
    Score: 0.034
  24. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6.
    View in: PubMed
    Score: 0.034
  25. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
    View in: PubMed
    Score: 0.025
  26. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008 Jun 15; 46(12):1844-51.
    View in: PubMed
    Score: 0.025
  27. Expanding tuberculosis case detection by screening household contacts. Public Health Rep. 2005 May-Jun; 120(3):271-7.
    View in: PubMed
    Score: 0.020
  28. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004 Feb 07; 363(9407):474-81.
    View in: PubMed
    Score: 0.018
  29. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28.
    View in: PubMed
    Score: 0.017
  30. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55.
    View in: PubMed
    Score: 0.015
  31. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2000 Feb; 4(2):108-14.
    View in: PubMed
    Score: 0.014
  32. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis. 2000 Feb; 19(2):132-6.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.